United Capital Financial Advisors LLC Makes New $1.07 Million Investment in Halozyme Therapeutics, Inc. $HALO

United Capital Financial Advisors LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 13,677 shares of the biopharmaceutical company’s stock, valued at approximately $1,070,000.

Several other institutional investors have also modified their holdings of the business. Arrowstreet Capital Limited Partnership increased its position in shares of Halozyme Therapeutics by 29.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock worth $241,337,000 after acquiring an additional 749,484 shares during the period. Bank of America Corp DE purchased a new position in Halozyme Therapeutics in the second quarter valued at $214,504,000. William Blair Investment Management LLC purchased a new position in Halozyme Therapeutics in the second quarter valued at $196,540,000. Dimensional Fund Advisors LP grew its stake in Halozyme Therapeutics by 1.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock worth $141,613,000 after purchasing an additional 25,731 shares in the last quarter. Finally, Norges Bank acquired a new position in Halozyme Therapeutics during the 4th quarter worth $128,201,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on HALO shares. UBS Group reaffirmed a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $83.00 to $110.00 in a report on Friday, August 7th. Morgan Stanley dropped their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $91.20.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $105.35 on Friday. The firm has a market capitalization of $11.96 billion, a P/E ratio of 31.45, a P/E/G ratio of 0.42 and a beta of 0.85. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $109.66. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The firm’s 50 day moving average is $87.01 and its two-hundred day moving average is $74.78.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the previous year, the firm earned $1.54 EPS. The company’s revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Research analysts forecast that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the sale, the director directly owned 14,462 shares of the company’s stock, valued at $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at $79,987,320.40. This represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 64,103 shares of company stock worth $5,226,496 in the last ninety days. 2.50% of the stock is owned by corporate insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.